CalciMedica is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. Co.'s product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, a potent inhibitor of neovascular growth and permeability, which are causes of retinal disease. Co.'s second product candidate, GB-401, is an intravitreally administered, proprietary implant formulation containing a prodrug of a beta-adrenergic receptor inhibitor developed to provide a controlled release of the active drug to maintain reduced intraocular pressure, for six months or longer after a single injection. We show 3 historical shares outstanding datapoints in our coverage of CALC's shares outstanding history.
Understanding the changing numbers of CALC shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like CALC versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching CALC by allowing them to research CALC shares outstanding history
as well as any other stock in our coverage universe. |
Free CALC Email Alerts:
Video: Shares Outstanding Importance
